8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Feb 26, 2026·SEC
Material company update
Jan 13, 2026·SEC
Cytek Biosciences, Inc.(CTKB)Earnings, Financials & Key Ratios
CTKB•NASDAQ
$4.92
$632M mkt cap·Price updated May 7, 2026
AboutCytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated plate loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.Show more
- Revenue$201M+0.5%
- EBITDA-$28M-183.2%
- Net Income-$67M-1005.3%
- EPS (Diluted)-0.52-1028.0%
- Gross Margin51.84%-6.5%
- EBITDA Margin-14.1%-181.7%
- Operating Margin-20.04%-95.8%
- Net Margin-33.02%-999.6%
- ROE-18.05%-1082.2%
- ROIC-10.13%-82.3%
- Debt/Equity0.10+124.7%
- Interest Coverage-61.96
CTKB Key Insights
Cytek Biosciences, Inc. (CTKB) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y sales CAGR of 16.8%
- ✓Share count reduced 2.2% through buybacks
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CTKB Price & Volume
Cytek Biosciences, Inc. (CTKB) stock price & volume — 10-year historical chart
Loading chart...
CTKB Growth Metrics
Cytek Biosciences, Inc. (CTKB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years16.76%
3 Years7.1%
TTM0.52%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-1005.48%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-1004.49%
Return on Capital
10 Years-5.99%
5 Years-3.64%
3 Years-6.92%
Last Year-9.9%
CTKB Recent Earnings
Cytek Biosciences, Inc. (CTKB) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 3/12 qtrs (25%)
Q1 2026Latest
Feb 26, 2026EPS
$0.01
Est $0.02
+50.0%
Revenue
$62M
Est $57M
+8.7%
Q4 2025
Nov 5, 2025EPS
$0.01
Est $0.01
-200.0%
Revenue
$52M
Est $59M
-11.1%
Q3 2025
Aug 6, 2025EPS
$0.01
Est $0.02
+150.0%
Revenue
$46M
Est $46M
-1.6%
Q2 2025
May 8, 2025EPS
$0.09
Est $0.04
-125.0%
Revenue
$41M
Est $43M
-2.8%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 26, 2026 | $0.01vs $0.02+50.0% | $62Mvs $57M+8.7% |
| Q4 2025 | Nov 5, 2025 | $0.01vs $0.01-200.0% | $52Mvs $59M-11.1% |
| Q3 2025 | Aug 6, 2025 | $0.01vs $0.02+150.0% | $46Mvs $46M-1.6% |
| Q2 2025 | May 8, 2025 | $0.09vs $0.04-125.0% | $41Mvs $43M-2.8% |
Based on last 12 quarters of dataView full earnings history →
CTKB Peer Comparison
Cytek Biosciences, Inc. (CTKB) competitors in Device suppliers, distribution, and services — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ILMN | 21.07B | 138.71 | 25.45 | -0.78% | 19.43% | 32.84% | 0.94 | |
 HOLX | 16.97B | 76.01 | 30.53 | 1.74% | 13.18% | 11.01% | 0.52 | |
 AZTA | 855.36M | 18.57 | -15.22 | 3.55% | -29.86% | -10.69% | 0.06 | |
 NTRA | 31.16B | 219.82 | -144.62 | 35.9% | -9.03% | -15.28% | 0.13 | |
 BIO | 6.95B | 257.32 | 9.23 | 0.65% | 6.52% | 2.4% | 0.21 | |
 BRKR | 6.66B | 43.73 | -291.53 | 2.08% | -0.34% | -0.5% | 0.81 | |
 WAT | 22.83B | 350.29 | 32.55 | 6.99% | 11.91% | 8.04% | 0.55 | |
 TMO | 176.36B | 474.56 | 26.75 | 3.91% | 15.18% | 13.23% | 0.76 |
Compare CTKB vs Peers
Cytek Biosciences, Inc. (CTKB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CTKB Income Statement
Cytek Biosciences, Inc. (CTKB) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 57.88M | 92.84M | 127.95M | 164.04M | 193.01M | 200.45M | 201.49M |
| Revenue Growth % | - | 60.39% | 37.82% | 28.2% | 17.67% | 3.85% | 0.52% |
| Cost of Goods Sold | 29.21M | 41.13M | 48.81M | 63.06M | 83.59M | 89.35M | 97.03M |
| COGS % of Revenue | 50.46% | 44.3% | 38.14% | 38.44% | 43.31% | 44.57% | 48.16% |
| Gross Profit | 28.67M▲ 0% | 51.71M▲ 80.3% | 79.14M▲ 53.1% | 100.97M▲ 27.6% | 109.43M▲ 8.4% | 111.11M▲ 1.5% | 104.46M▼ 6.0% |
| Gross Margin % | 49.54% | 55.7% | 61.86% | 61.56% | 56.69% | 55.43% | 51.84% |
| Gross Profit Growth % | - | 80.34% | 53.05% | 27.58% | 8.37% | 1.54% | -5.98% |
| Operating Expenses | 45.93M | 38.05M | 69.99M | 102.78M | 137.27M | 131.63M | 144.84M |
| OpEx % of Revenue | 79.35% | 40.99% | 54.7% | 62.66% | 71.12% | 65.67% | 71.89% |
| Selling, General & Admin | 16.98M | 24.36M | 45.55M | 67.92M | 93.12M | 92.23M | 108.38M |
| SG&A % of Revenue | 29.34% | 26.24% | 35.6% | 41.41% | 48.24% | 46.01% | 53.79% |
| Research & Development | 8.93M | 13.69M | 24.44M | 34.86M | 44.15M | 39.4M | 36.47M |
| R&D % of Revenue | 15.43% | 14.75% | 19.1% | 21.25% | 22.87% | 19.66% | 18.1% |
| Other Operating Expenses | 20.02M | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -17.26M▲ 0% | 13.66M▲ 179.2% | 9.16M▼ 33.0% | -1.8M▼ 119.7% | -27.84M▼ 1443.5% | -20.52M▲ 26.3% | -40.38M▼ 96.8% |
| Operating Margin % | -29.81% | 14.71% | 7.16% | -1.1% | -14.43% | -10.24% | -20.04% |
| Operating Income Growth % | - | 179.16% | -32.96% | -119.7% | -1443.51% | 26.3% | -96.77% |
| EBITDA | -16.95M | 14.26M | 10.4M | 3.85M | -18.61M | -10.03M | -28.41M |
| EBITDA Margin % | -29.28% | 15.36% | 8.13% | 2.35% | -9.64% | -5.01% | -14.1% |
| EBITDA Growth % | - | 184.16% | -27.09% | -62.93% | -582.88% | 46.1% | -183.16% |
| D&A (Non-Cash Add-back) | 309K | 603K | 1.24M | 5.66M | 9.23M | 10.49M | 11.97M |
| EBIT | -16.29M | 14.76M | 7.68M | 3.83M | -13.64M | -20.52M | -29.37M |
| Net Interest Income | 710K | -223K | -1.69M | 2.05M | 4.34M | 10.36M | 1.74M |
| Interest Income | 711K | 110K | 49K | 4.62M | 6.41M | 10.36M | 2.22M |
| Interest Expense | 1K | 333K | 1.74M | 2.57M | 2.07M | 0 | 474K |
| Other Income/Expense | 962K | 771K | -3.22M | 3.06M | 12.14M | 14.82M | 10.54M |
| Pretax Income | -16.29M▲ 0% | 14.43M▲ 188.6% | 5.94M▼ 58.8% | 1.26M▼ 78.8% | -15.71M▼ 1346.7% | -5.7M▲ 63.7% | -29.84M▼ 423.5% |
| Pretax Margin % | -28.15% | 15.54% | 4.64% | 0.77% | -8.14% | -2.84% | -14.81% |
| Income Tax | 533K | -4.98M | 2.91M | -1.22M | -3.56M | 320K | 36.7M |
| Effective Tax Rate % | -3.27% | -34.52% | 49.02% | -97.14% | 22.67% | -5.61% | -122.98% |
| Net Income | -16.83M▲ 0% | 19.41M▲ 215.4% | 3M▼ 84.5% | 2.58M▼ 14.2% | -12.15M▼ 571.6% | -6.02M▲ 50.4% | -66.54M▼ 1005.3% |
| Net Margin % | -29.07% | 20.91% | 2.35% | 1.57% | -6.29% | -3% | -33.02% |
| Net Income Growth % | - | 215.36% | -84.54% | -14.16% | -571.58% | 50.44% | -1005.3% |
| Net Income (Continuing) | -16.83M | 19.41M | 3.03M | 2.48M | -12.15M | -6.02M | -66.54M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 343K | 251K | 0 | 0 | 0 |
| EPS (Diluted) | -0.13▲ 0% | 0.02▲ 118.6% | 0.03▲ 36.4% | 0.02▼ 43.6% | -0.09▼ 582.8% | -0.05▲ 48.7% | -0.52▼ 1028.0% |
| EPS Growth % | - | 118.62% | 36.36% | -43.64% | -582.8% | 48.66% | -1027.98% |
| EPS (Basic) | -0.13 | 0.02 | 0.03 | 0.02 | -0.09 | -0.05 | -0.52 |
| Diluted Shares Outstanding | 132.99M | 132.99M | 133.75M | 138.56M | 135.28M | 130.61M | 127.75M |
| Basic Shares Outstanding | 132.99M | 132.99M | 133.75M | 134.51M | 135.28M | 130.61M | 127.75M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
CTKB Balance Sheet
Cytek Biosciences, Inc. (CTKB) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 67.77M | 208.62M | 431.73M | 454.02M | 392.06M | 396.45M | 392M |
| Cash & Short-Term Investments | 30.12M | 165.23M | 364.62M | 341.15M | 262.41M | 277.86M | 261.53M |
| Cash Only | 30.12M | 165.23M | 364.62M | 296.6M | 167.3M | 98.72M | 90.85M |
| Short-Term Investments | 0 | 0 | 0 | 44.55M | 95.11M | 179.15M | 170.68M |
| Accounts Receivable | 17.75M | 18.1M | 29.63M | 50.88M | 56.12M | 60.59M | 72.13M |
| Days Sales Outstanding | 111.9 | 71.18 | 84.53 | 113.2 | 106.13 | 110.32 | 130.66 |
| Inventory | 18.43M | 23.02M | 32.17M | 48.15M | 60.88M | 43.89M | 48.43M |
| Days Inventory Outstanding | 230.35 | 204.27 | 240.59 | 278.71 | 265.83 | 179.31 | 182.17 |
| Other Current Assets | 419K | 1.33M | 708K | 6.7M | 2.56M | 1.97M | 9.91M |
| Total Non-Current Assets | 2.6M | 11.36M | 31.57M | 65.46M | 102.4M | 103.05M | 69.55M |
| Property, Plant & Equipment | 1.04M | 2.14M | 5.85M | 27.57M | 29.26M | 28.13M | 29.32M |
| Fixed Asset Turnover | 55.60x | 43.38x | 21.87x | 5.95x | 6.60x | 7.13x | 6.87x |
| Goodwill | 476K | 476K | 10.14M | 10.14M | 16.18M | 16.66M | 16.7M |
| Intangible Assets | 263K | 274K | 4.74M | 4.33M | 23.08M | 20.13M | 16.82M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 1.6M | 1.6M | 0 |
| Other Non-Current Assets | 816K | 1.09M | 1.67M | 2.96M | 1.78M | 3.16M | 6.7M |
| Total Assets | 70.36M▲ 0% | 219.98M▲ 212.6% | 463.31M▲ 110.6% | 519.48M▲ 12.1% | 494.46M▼ 4.8% | 499.5M▲ 1.0% | 461.54M▼ 7.6% |
| Asset Turnover | 0.82x | 0.42x | 0.28x | 0.32x | 0.39x | 0.40x | 0.44x |
| Asset Growth % | - | 212.64% | 110.61% | 12.12% | -4.82% | 1.02% | -7.6% |
| Total Current Liabilities | 21.04M | 26.54M | 33.18M | 49.04M | 56.23M | 67.66M | 77.8M |
| Accounts Payable | 2.34M | 2.94M | 3.03M | 4.8M | 3.03M | 5.53M | 6.41M |
| Days Payables Outstanding | 29.27 | 26.13 | 22.69 | 27.81 | 13.24 | 22.59 | 24.11 |
| Short-Term Debt | 0 | 2.77M | 0 | 580K | 565K | 4.66M | 11.67M |
| Deferred Revenue (Current) | 3.47M | 4.29M | 8.1M | 14.54M | 22.7M | 26.61M | 28.5M |
| Other Current Liabilities | 10.51M | 12.01M | 12.04M | 17.3M | 21.2M | 1.86M | 31.22M |
| Current Ratio | 3.22x | 7.86x | 13.01x | 9.26x | 6.97x | 5.86x | 5.04x |
| Quick Ratio | 2.34x | 6.99x | 12.04x | 8.28x | 5.89x | 5.21x | 4.42x |
| Cash Conversion Cycle | 312.99 | 249.32 | 302.44 | 364.11 | 358.71 | 267.05 | 288.71 |
| Total Non-Current Liabilities | 91.02M | 209.47M | 24.74M | 44.89M | 45.17M | 36.1M | 42M |
| Long-Term Debt | 0 | 0 | 0 | 2.27M | 1.65M | 1.05M | 7.31M |
| Capital Lease Obligations | 0 | 0 | 0 | 12.31M | 9.48M | 7.55M | 14.04M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 89.24M | 206.01M | 14.95M | 17.18M | 18.91M | 11.4M | 9.09M |
| Total Liabilities | 112.06M | 236.01M | 57.92M | 93.93M | 101.39M | 103.76M | 119.8M |
| Total Debt | 0 | 2.77M | 0 | 18.09M | 14.14M | 17.02M | 33.02M |
| Net Debt | -30.12M | -162.46M | -364.62M | -278.51M | -153.16M | -81.7M | -57.83M |
| Debt / Equity | - | - | - | 0.04x | 0.04x | 0.04x | 0.10x |
| Debt / EBITDA | - | 0.19x | - | 4.69x | - | - | - |
| Net Debt / EBITDA | - | -11.39x | -35.06x | -72.25x | - | - | - |
| Interest Coverage | -16293.00x | 44.33x | 4.41x | 1.49x | -6.59x | - | -61.96x |
| Total Equity | -41.7M▲ 0% | -16.03M▲ 61.6% | 405.38M▲ 2629.2% | 425.55M▲ 5.0% | 393.06M▼ 7.6% | 395.74M▲ 0.7% | 341.74M▼ 13.6% |
| Equity Growth % | - | 61.56% | 2629.23% | 4.97% | -7.63% | 0.68% | -13.64% |
| Book Value per Share | -0.31 | -0.12 | 3.03 | 3.07 | 2.91 | 3.03 | 2.68 |
| Total Shareholders' Equity | -41.7M | -16.03M | 405.04M | 425.3M | 393.06M | 395.74M | 341.74M |
| Common Stock | 21K | 23K | 126K | 135K | 131K | 129K | 129K |
| Retained Earnings | -42.02M | -22.61M | -19.61M | -17.03M | -29.18M | -35.2M | -101.74M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -147K | 65K | 897K | -697K | -1.27M | 16K | 2.24M |
| Minority Interest | 0 | 0 | 343K | 251K | 0 | 0 | 0 |
CTKB Cash Flow Statement
Cytek Biosciences, Inc. (CTKB) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -13.75M | 15.16M | 4.63M | -12.23M | 5.28M | 25.38M | -4.69M |
| Operating CF Margin % | -23.75% | 16.32% | 3.62% | -7.46% | 2.74% | 12.66% | -2.33% |
| Operating CF Growth % | - | 210.25% | -69.45% | -364.17% | 143.18% | 380.57% | -118.46% |
| Net Income | -16.83M | 19.41M | 3.03M | 2.48M | -12.15M | -6.02M | -66.54M |
| Depreciation & Amortization | 309K | 603K | 1.24M | 5.66M | 9.23M | 10.49M | 11.97M |
| Stock-Based Compensation | 269K | 611K | 6.59M | 16.59M | 22.05M | 26.85M | 24.59M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | -2.89M | 33.56M |
| Other Non-Cash Items | 1.34M | 2.07M | 2.42M | 2.96M | -3.34M | -10.77M | -3.47M |
| Working Capital Changes | 1.16M | -7.54M | -8.65M | -39.93M | -10.51M | 7.71M | -4.79M |
| Change in Receivables | -12.61M | 334K | -12.37M | -19.74M | -7.33M | -5.43M | 368K |
| Change in Inventory | -14.61M | -5.7M | -7.07M | -17.65M | 4.29M | 14.76M | -5.24M |
| Change in Payables | 1.21M | -55K | -256K | 1.86M | -1.78M | 2.58M | 448K |
| Cash from Investing | -973K | -1.55M | -20.99M | -55.91M | -93.89M | -82.97M | 10.12M |
| Capital Expenditures | -973K | -1.55M | -4.36M | -9.75M | -4.65M | -3.52M | -4.08M |
| CapEx % of Revenue | 1.68% | 1.67% | 3.41% | 5.94% | 2.41% | 1.76% | 2.03% |
| Acquisitions | 0 | 0 | -16.63M | 0 | -45.13M | -471K | 252K |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | -120K | -179K | 84K | -107K |
| Cash from Financing | 93K | 122.61M | 213.56M | 5.51M | -41.81M | -15.82M | -13.43M |
| Debt Issued (Net) | 0 | 2.77M | -2.77M | 2.93M | -565K | 3.62M | 837K |
| Equity Issued (Net) | 0 | 119.67M | 215.69M | 0 | -44.15M | -21.61M | -13.6M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | -44.15M | -21.61M | -15.07M |
| Other Financing | 93K | 169K | 642K | 2.58M | 2.9M | 2.17M | -669K |
| Net Change in Cash | -14.66M▲ 0% | 135.63M▲ 1025.2% | 198.5M▲ 46.4% | -65.12M▼ 132.8% | -131.87M▼ 102.5% | -68.89M▲ 47.8% | -7.89M▲ 88.5% |
| Free Cash Flow | -14.72M▲ 0% | 13.61M▲ 192.5% | 266K▼ 98.0% | -22.1M▼ 8407.9% | 454K▲ 102.1% | 21.85M▲ 4713.7% | -8.77M▼ 140.1% |
| FCF Margin % | -25.43% | 14.66% | 0.21% | -13.47% | 0.24% | 10.9% | -4.35% |
| FCF Growth % | - | 192.45% | -98.05% | -8407.89% | 102.05% | 4713.66% | -140.13% |
| FCF per Share | -0.11 | 0.10 | 0.00 | -0.16 | 0.00 | 0.17 | -0.07 |
| FCF Conversion (FCF/Net Income) | 0.82x | 0.78x | 1.54x | -4.75x | -0.43x | -4.22x | 0.07x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 144K | 2.07M | 2.86M | 10.39M | 5.3M | 3.83M | 0 |
CTKB Key Ratios
Cytek Biosciences, Inc. (CTKB) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | 1.54% | 0.62% | -2.97% | -1.53% | -18.05% |
| Return on Invested Capital (ROIC) | - | - | 16.85% | -1.44% | -10.79% | -5.56% | -10.13% |
| Gross Margin | 49.54% | 55.7% | 61.86% | 61.56% | 56.69% | 55.43% | 51.84% |
| Net Margin | -29.07% | 20.91% | 2.35% | 1.57% | -6.29% | -3% | -33.02% |
| Debt / Equity | - | - | - | 0.04x | 0.04x | 0.04x | 0.10x |
| Interest Coverage | -16293.00x | 44.33x | 4.41x | 1.49x | -6.59x | - | -61.96x |
| FCF Conversion | 0.82x | 0.78x | 1.54x | -4.75x | -0.43x | -4.22x | 0.07x |
| Revenue Growth | - | 60.39% | 37.82% | 28.2% | 17.67% | 3.85% | 0.52% |
CTKB SEC Filings & Documents
Cytek Biosciences, Inc. (CTKB) SEC filings — annual & quarterly reports (10-K, 10-Q)
CTKB Frequently Asked Questions
Cytek Biosciences, Inc. (CTKB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Cytek Biosciences, Inc. (CTKB) reported $201.5M in revenue for fiscal year 2025. This represents a 248% increase from $57.9M in 2019.
Cytek Biosciences, Inc. (CTKB) grew revenue by 0.5% over the past year. Growth has been modest.
Cytek Biosciences, Inc. (CTKB) reported a net loss of $66.5M for fiscal year 2025.
Dividend & Returns
Cytek Biosciences, Inc. (CTKB) has a return on equity (ROE) of -18.0%. Negative ROE indicates the company is unprofitable.
Cytek Biosciences, Inc. (CTKB) had negative free cash flow of $8.8M in fiscal year 2025, likely due to heavy capital investments.
Explore More CTKB
Cytek Biosciences, Inc. (CTKB) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates